These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
149 related items for PubMed ID: 12743448
1. Acenocoumarol is not a safe alternative for anticoagulation in phenprocoumon-induced hepatic failure. Report of two cases. Neef M, Kerekes Z, Fischer HP, Sauerbruch T, Spengler U. Digestion; 2003; 67(1-2):100-4. PubMed ID: 12743448 [Abstract] [Full Text] [Related]
3. [Off label use in long-term anticoagulation after liver transplantation due to phenprocoumon-induced hepatic failure]. Bertsche T, Fritz R, Sauer P, Encke J, Haefeli WE, Walter-Sack I. Med Monatsschr Pharm; 2006 Jul; 29(7):257-62. PubMed ID: 16866079 [Abstract] [Full Text] [Related]
4. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Gadisseur AP, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Br J Haematol; 2002 Jun; 117(4):940-6. PubMed ID: 12060134 [Abstract] [Full Text] [Related]
9. [Liver injury caused by coumarin anticoagulants: experience of the IKS (Intercanton Monitoring Station) and the SANZ (Swiss Center for Drug Monitoring)]. Ciorciaro C, Hartmann K, Stoller R, Kuhn M. Schweiz Med Wochenschr; 1996 Dec 07; 126(49):2109-13. PubMed ID: 8999497 [Abstract] [Full Text] [Related]
10. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon. Becker ML, Franken WP, Karapinar F, Verzijl-Zeegers R, Schalekamp T, van der Hoeven RT. Eur J Clin Pharmacol; 2015 Dec 07; 71(12):1461-5. PubMed ID: 26400679 [Abstract] [Full Text] [Related]
13. Subtherapeutic oral anticoagulant therapy: frequency and risk factors. Rombouts EK, Rosendaal FR, van der Meer FJ. Thromb Haemost; 2009 Mar 07; 101(3):552-6. PubMed ID: 19277419 [Abstract] [Full Text] [Related]
14. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Clin Pharmacol Ther; 2001 Jun 07; 69(6):451-7. PubMed ID: 11406743 [Abstract] [Full Text] [Related]
15. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Thromb Haemost; 2004 Jul 07; 92(1):61-6. PubMed ID: 15213846 [Abstract] [Full Text] [Related]